Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California.…
Oncology Institute Q3 Earnings Call Highlights
Starling Oncology (NASDAQ: STLN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 641 employees.
The shares were at 3.000 USD on 20 November 2026, down 15.4% over 52 weeks. Its 52-week range is 2.320 USD to 7.130 USD: the price is 57.9% below the high and 29.3% above the low.
Its market capitalisation is 305.97M USD.
Starling Oncology reports return on equity of 385.5%, an operating margin of -3.4% and revenue up 24.3% year over year.
Its debt exceeds its cash by 65.88M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 4 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 9.250 USD is 208.3% above the current price. The next earnings report is expected on 11 March 2027.